Please login to the form below

Not currently logged in
Email:
Password:

GSK benefiting from joint R&D

GlaxoSmithKline and Pozen announced on April 17 that the US Food and Drug Administration has approved the migraine medication Treximet
GlaxoSmithKline (GSK) and Pozen announced on April 17 that the US Food and Drug Administration (FDA) has approved the migraine medication Treximet.

Treximet has been developed to treat migraine and could be available in the US market as early as mid-May 2008. Trials into the drug have shown it to be more effective than sumatriptan and naproxen, two existing migraine medications, both of which are components of Treximet.

More than 3,700 migraine patients have been involved in extensive clinical trials that saw Treximet used to treat almost 30,000 migraine attacks.

Dr Stephen Silberstein, professor of neurology and director of the Jefferson Headache Centre at Thomas Jefferson University, said: "The FDA approval of Treximet is good news for migraine patients because clinical trials showed that Treximet produced sustained migraine pain relief for a significant number of patients."

"Migraine patients want their medicine to work early and to continue to provide relief," he added.

GSK has also announced an alliance with Regulus Therapeutics to launch an R&D programme to discover novel microRNA-targeted therapeutics for treating inflammatory conditions, such as rheumatoid arthritis and bowel disease. Regulus will be given a $20m upfront payment as part of the deal.

17th April 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fendix

Latest intelligence

Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...
Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
Geoff
Cancer care – the power of new technologies
With patient numbers set to soar, how can we make a difference?...

Infographics